Genflow Biosciences plc
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a GENF.L research report →
Companygenflowbio.com
Genflow Biosciences plc operates as a biotechnology company that focuses on developing biological interventions aimed at tackling the effects of ageing, slowing or halting the ageing process, and reducing the incidence of age-related diseases with increase in health span. Its lead compound is GF-1002, a suspension of an adeno-associated viral vector-based gene therapy for intravenous infusion. The company is also developing GF-3001, a topical delivery of SIRT6 to the skin; and GF-4001, a non-human pipeline anti-aging for veterinary use.
- CEO
- Eric Jean Leire
- IPO
- 2022
- Employees
- 5
- HQ
- London, GB
Price Chart
Valuation
- Market Cap
- $11.69M
- P/E
- -6.25
- P/S
- -77.45
- P/B
- -26.20
- EV/EBITDA
- -9.00
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 100.00%
- Op Margin
- 734.61%
- Net Margin
- 840.76%
- ROE
- 377.33%
- ROIC
- 365.96%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-1,417,564 · 10.69%
- EPS
- $-0.00 · 29.79%
- Op Income
- $-2,003,171
- FCF YoY
- -32.74%
Performance & Tape
- 52W High
- $3.12
- 52W Low
- $0.55
- 50D MA
- $2.20
- 200D MA
- $1.80
- Beta
- 2.11
- Avg Volume
- 2.17M
Get TickerSpark's AI analysis on GENF.L
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our GENF.L Coverage
We haven't published any research on GENF.L yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate GENF.L Report →